{"id":"tvp-1012","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"S1PR1 is a key regulator of lymphocyte trafficking and homing. By targeting S1PR1, TVP-1012 aims to reduce lymphocyte infiltration into tissues, which is a hallmark of autoimmune diseases.","oneSentence":"TVP-1012 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:37.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT02337764","phase":"PHASE3","title":"A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-02-03","conditions":"Parkinson's Disease","enrollment":222},{"nctId":"NCT02337751","phase":"PHASE3","title":"A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-07-10","conditions":"Parkinson's Disease","enrollment":198},{"nctId":"NCT02337738","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-01-27","conditions":"Parkinson's Disease","enrollment":404},{"nctId":"NCT02337725","phase":"PHASE3","title":"A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-02-07","conditions":"Parkinson's Disease","enrollment":244},{"nctId":"NCT01723228","phase":"PHASE4","title":"Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-11","conditions":"Parkinson's Disease","enrollment":170},{"nctId":"NCT01049984","phase":"PHASE4","title":"Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2009-12","conditions":"Parkinson's Disease","enrollment":328},{"nctId":"NCT00977665","phase":"PHASE2","title":"Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-12","conditions":"Multiple System Atrophy","enrollment":174},{"nctId":"NCT01879748","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-06","conditions":"Parkinson's Disease","enrollment":64},{"nctId":"NCT01709461","phase":"","title":"Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2012-10","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT00203125","phase":"PHASE3","title":"A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2000-10","conditions":"Parkinson's Disease","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TVP-1012","genericName":"TVP-1012","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TVP-1012 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}